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ABSTRACT 
Introduction: Traumatic Brain Injury (TBI) is a leading cause of death and disability 
in young people, affecting 69 million people annually, worldwide. The initial trauma 
disrupts brain homeostasis resulting in metabolic dysfunction and an inflammatory 
cascade, which can then promote further neurodegenerative effects for months or 
years, as a ‘secondary’ injury. Effective targeting of the cerebral inflammatory system 
is challenging due to its complex, pleiotropic nature. Cell metabolism plays a key role 
in many diseases, and increased disturbance in the TBI metabolic state is 
associated with poorer patient outcomes. Investigating critical metabolic pathways, 
and their links to inflammation, can pot ntially identify supplements which alter the 
brain’s long-term response to TBI and improve recovery. 
Areas covered:  The authors provide an overview of literature on metabolism and 
inflammation following TBI, and from relevant pre-clinical and clinical studies, 
propose therapeutic strategies.
Expert commentary: There is still no specific active drug treatment for TBI. 
Changes in metabolic and inflammatory states have been reported after TBI and 
appear linked. Understanding more about abnormal cerebral metabolism following 
TBI, and its relationship with cerebral inflammation, will provide essential information 
for designing therapies, with implications for neurocritical care and for alleviating 
long-term disability and neurodegeneration in post-TBI patients.
KEYWORDS: Inflammation, Lactate Pyruvate Ratio (LPR), Metabolic Dysfunction, 
Metabolism, Supplementation, Traumatic brain injury (TBI). 
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1.0 Traumatic brain injury
Traumatic Brain Injury (TBI) is the leading cause of death and disability for those 
under 40 years of age in the developed world [1,2]. While an estimated 69 million 
people are affected worldwide every year [3], there has been significant progress in 
the last century to combat the extent of such injuries. Public policies such as road 
safety measures and occupational health and safety regulations can decrease the 
incidence of TBI, and advanced neurocritical care has improved individual patient 
management. Multi-modality monitoring is one of such advancements which enables 
real-time observation of cerebral pressure and oxygenation. Clinicians can then 
attempt to resolve disturbances in these parameters of the brain using surgical and 
medical interventions. Despite the progress in these areas and our improved 
understanding of the brain in recent decades, there is still no standard effective drug 
treatment for TBI. There is a great opportunity for such treatment to mitigate the 
extent of tissue damage and cell death, however many clinical and pre-clinical trials 
that have seemed promising in earlier stages have failed to show significant benefit 
when implemented in patients [4]. This may be due to a number of things, including 
issues with animal model to human translation, lack of trial optimisation in humans, 
the heterogeneous nature of the injuries, shortcomings of the Glasgow Outcome 
Scale (GOS) in assessing smaller improvements, and the complexity of targeting the 
inflammatory system due to the pleiotropic nature of its components [5]. 
Initial or ‘primary’ trauma of the brain is caused by impact and physical movement of 
the brain, resulting in damage of blood vessels, damage to cell axons, shearing of 
tissue, and swelling. The ‘secondary’ injury of continued degeneration, however, is 
less well understood and can vary vastly between patients with similar injuries. TBI is 
a heterogenous disease ranging in severity; this review is focussed on severe TBI in 
the context of neurocritical care. Recent studies have highlighted the high 
occurrence of chronic traumatic encephalopathy in players of contact sports, and 
how multiple mild head injury events can lead to chronic traumatic encephalopathy 
with dementia and Parkinson’s-like symptoms [6]. Mild TBI and multi-injury 
concussive brain injury patients differ from severe TBI patients in terms of pathology 
[7,8], inflammatory activation levels [9], and brain metabolic changes [10]. Caution 
and additional research must therefore be taken when applying treatments proposed 
for single-injury severe TBI patients in this review to other forms of TBI. 
In the days following severe TBI, we see a prominent inflammatory cascade in the 
majority of patients [11], with subsets of patients experiencing a chronic inflammation 
for many months or even years post-injury, accompanied by cognitive 
neurodegeneration [12]. Mitochondrial dysfunction is also a hallmark of both the 
acute and post-acute stages of severe TBI, with changes in mitochondrial 
morphology [13], accumulation of mitochondria at injury sites, altered levels of 
metabolites and overall mitochondrial function [14,15]. There is increasing evidence 
that these two phenomena of inflammation and mitochondrial metabolism have 
significant cross-talk and impact upon one another in multiple other disease states of 
Page 2 of 39
URL: https://mc.manuscriptcentral.com/ern   Email: IERN-peerreview@journals.tandf.co.uk





























































For Peer Review Only
3
the brain, including multiple sclerosis [16], Parkinson’s [17], Alzheimer’s [18,19], and 
amyotrophic lateral sclerosis [20]. This relationship also warrants investigation in 
TBI, and any mechanistic links between metabolism and inflammation may be key 
for dual-acting therapies which can ameliorate the negative effects of both pathways.
This review will outline the critical roles and interaction of metabolism and 
inflammation in TBI, highlighting the implications of these interactions for potential 
therapeutic strategies. As this is an emerging field of interest, evidence of such 
interaction between the two processes in several disease models will be presented, 
along with the case for further research into the important relationship.
2.0 Brain Metabolism
2.1. Fundamentals of metabolism 
The brain requires around 20% of the body’s total energy output to send electrical 
signals and maintain homeostatic function. Cellular metabolism provides the energy 
that underlies all brain activity by processing substrates into ATP. Glucose is the 
main source of fuel for energy production in the brain, but the mechanism of its 
consumption varies in different environmental conditions and between different cell 
types, with downstream substrates such as lactate purported to play a key role [21]. 
Glycolysis, the initial breakdown of glucose molecules, produces a low yield of 2 
molecules of ATP per molecule of glucose, and 2 pyruvate molecules, which can 
subsequently be used for further energy production (Figure 1). After glycolysis, the 
pyruvate molecules can go on to be converted to lactate with no additional ATP 
produced, or used in the high yield oxidative phosphorylation pathway, through the 
tricarboxylic acid (TCA) cycle and electron transport chain (ETC). The energy yield 
per molecule of glucose metabolised fully to CO2 (by the combination of glycolysis, 
NADH shuttling and mitochondrial respiration) is theoretically 36–38 molecules of 
ATP, but the actual yield is considered somewhat lower [22,23]. 
The pentose phosphate pathway (PPP) is yet another potential fate of a glucose 
molecule, diverging from initial glycolysis steps, which produces no ATP but does 
produce molecules for nucleic acid sequences. The PPP is a complex biosynthetic 
network constituting a detour around several steps of glycolysis, generating many 
species including lactate and does not involve molecular oxygen. Its main function 
can be regarded as sacrificing some of the cells’ supply of glucose molecules, which 
might otherwise have been used for ATP synthesis, for the sake of generating more 
reducing power (NADPH) and the ability to protect, repair, or build cells.
Another energetic pathway theory which is gaining in acceptance (although still 
debated) is the astrocyte-neuron lactate shuttle (ANLS) hypothesis [24,25]. In the 
ANLS theory, glycolysis - the conversion of glucose to pyruvate - occurs 
predominantly in astrocytes, followed by the subsequent conversion of pyruvate to 
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lactate by lactate dehydrogenase (LDH). The lactate is exported from astrocytes 
then transported by monocarboxylate transport proteins (MCT) into neurons where it 
can be oxidized back to pyruvate for entry into the TCA cycle. The astrocyte-neuron 
lactate shuttle (ANLS) is depicted schematically in Figure 2 and explained further in 
the legend [26]. 
The advantages of this transfer of lactate include the ability to maintain brain function 
by supporting neurons at the energetic cost of the astrocytes. Neurons, for example, 
have reduced expression of enzymes that detoxify by-products of glycolysis 
(glyoxase 1 and 2) compared to astrocytes [26]. Also, in comparison to neurons, 
astrocytes have lower activity of pyruvate dehydrogenase, which processes pyruvate 
for use in the TCA cycle [26], and a higher concentration of lactate (considered as a 
reservoir) [27,28]. Further evidence to support specific cell type metabolic substrate 
preferences is detailed in neocortical cell culture models [29] and in positive 
implications from small studies of human patients [30]. However, findings of a kinetic 
modelling study in rats using labelled glucose [31] favoured an “independent” model 
in which neurons and astrocytes take up and oxidise glucose according to their 
respective energy needs, rather than the ANLS model. It still remains to be shown 
directly that there is net transfer of lactate from glia to neurons in vivo, nevertheless it 
is important to consider the potential energetic impacts of such processes in our 
evolving understanding of brain metabolism. 
Whether glucose or lactate molecules are the primary source of fuel for neuronal 
cells, maintaining optimum energetic functioning of the brain can thus be achieved 
by utilising multiple metabolic substrates. The evidence of flexibility in the uptake and 
use of such molecules highlights a wider range of potential targets for energetic 
supplementation. Optimal energy processing in both homeostasis and injury is 
therefore an important aspect for further research as it may assist in recovery.
2.2 Metabolism in traumatic brain injury
Distinct changes in brain metabolism become apparent when brain cells are stressed 
by TBI [32]. Metabolic indicators of the glycolysis pathway are increased, as well as 
the presence of extracellular lactate, producing a high extracellular lactate to 
pyruvate ratio (LPR) in some TBI patients. LPR is often used as an indicator of the 
brain’s overall metabolic state in TBI, with a high LPR reflecting mitochondrial 
dysfunction or a lack of oxygen supply [15]. Increased lactate production from 
pyruvate may also reduce the total pyruvate available for mitochondrial metabolism, 
and as such reduce overall ATP production. 
Prior to surgical and medical interventions, a severe head injury or insult would likely 
cause a lack of oxygen to brain cells – hypoxia, so this switch to glycolysis may 
simply be an evolutionary coping mechanism, to ensure that energy production can 
still occur. Glycolysis and pyruvate to lactate conversion occurs without the need for 
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oxygen, unlike mitochondrial energy processing, and as such, cerebral hypoxia in 
TBI patients is also accompanied by an increase in glutamate and lactate levels [33]. 
The pentose phosphate pathway (PPP) [34] also does not require oxygen and may 
be another source of increased lactate post-TBI. In a recent small study, several TBI 
patients had PPP-derived lactate elevation above “normal” (non-TBI) brain ranges, 
correlating with decreasing brain tissue oxygen concentrations, indicating shifting 
glucose metabolism from glycolysis towards PPP (although with glycolysis remaining 
dominant) [34]. 
These perturbation in brain metabolism however can still occur in TBI patients even 
when access to oxygen is well conserved by clinical management strategies. Despite 
modern neurocritical care supplying the brain with seemingly adequate levels of 
oxygen and nutrients (e.g. glucose), the injured brain cannot always use the fuels it 
receives. Such patients suffering metabolic dysfunction (characterised by a high 
LPR) had significantly poorer clinical outcomes in a large study (223 patients) [15]. 
The divergence from normal metabolic function despite adequate oxygen, may imply 
that the change in metabolism may be associated with additional functions than just 
that of producing energy, such as involvement in the other key mechanisms which 
cope with injury, like inflammation. 
Reliance on the glycolysis pathway for energy production in TBI may also be due to 
damage sustained by the mitochondria [35]. Complex I of the mitochondrial electron 
transport chain is thought to be a likely site of impairment or alteration in activity in 
both TBI [36] and neurodegenerative disorders such as Parkinson’s [37], multiple 
sclerosis [38] and amyotrophic lateral sclerosis [39,40]. It has been demonstrated in 
animal models that the function of complex I decreases with age, and that it is 
particularly vulnerable to reactive oxygen species (ROS) which are produced 
adjacent to the complex [41]. The purported cause of this vulnerability is credited to 
the large proportion of mitochondrial rather than nuclear DNA subunits encoding 
complex I [42]. It is well established that mitochondrial DNA functionality decreases 
with age in various rodent tissues [43], accompanied by an increase in mitochondrial 
ROS production [41]. 
The fragile complex 1 may be too damaged post-TBI to utilize metabolic substrates, 
causing the observed extracellular accumulation and high LPR in patients [44]. 
Targeted supplementation of the brain’s mitochondria for rescuing the TCA cycle and 
sites of damage are therefore a prospective avenue for therapeutics. Recovering 
metabolic function may also contribute towards the whole brain response towards 
more reparative mechanisms such as inflammation, as detailed further in section 4. 
3.0 Inflammation in TBI
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The mechanism by which the force and impact of a TBI stimulates cells to initiate 
inflammatory signals is not fully understood. The trauma results in cellular debris and 
Disease Associated Molecular Patterns (DAMPs) including free DNA, RNA and 
alarmins such as HMGB1[45,46]. This begins the sequence of the inflammatory 
cascade, which activates and recruits both resident and peripheral immune cells. 
The inflammatory cascade initiates for a number of beneficial functions, including the 
phagocytosis and clearing of dead cells, the isolation of healthy brain area by ‘walls’ 
of microglia and astrocytes, and protection against infection [47]. However, 
persistent or unregulated inflammation can inflict ‘secondary insults’ on the brain, 
and it is difficult to detect at what point this inflammation becomes maladaptive [48]. 
Inflammatory processes in combination with a cytotoxic environment may lead to the 
excessive pruning of still-functioning synapses and engulfing of viable cells. This 
chronic level of inflammation and activated immune cells, which have been identified 
up to 17 years post-injury in patients, may play a significant role in the decrease of 
white matter density and corresponding reduction in cognitive ability [12,49].
There is an opportunity to intervene with treatments to limit this chronic inflammatory 
process, however, it is difficult differentiate the beneficial inflammation from the 
harmful. Inflammation in the brain post-injury could potentially be modulated by the 
use of targeted anti-inflammatory treatments (e.g. IL-1ra), as these may reduce the 
negative effects of this cascade [50]. However, a refined approach is required to 
maintain the beneficial aspects of inflammation such as repair and promotion cell 
survival [11], as anti-inflammatory therapies may therefore also impact on these 
restorative processes.
In ideal circumstances acute inflammation in the brain is self-resolving, yet the exact 
processes that govern the cascade or how to ‘switch’ from encouraging cell 
apoptosis, clearance and stress signals, to promoting cell survival and repair in vivo 
remain uncharacterised. Thelin et al. [51] have further described the complexity of 
the post-TBI environment, detailing the interactions between cell types and 
highlighting key signalling molecules, shown schematically in Figure 3 and explained 
in the legend. The complement system, for example, may contribute to 
neurodegeneration in TBI, as it enhances the inflammatory cascade. Complement, 
(for example C1q, C3b, C3d, C5-9) is increased in the brain post-injury and in 
microglia specifically – evidence has shown that this increase may influence their 
activation state, stimulate accumulation of inflammatory cells and formation of brain 
edemas and further neuronal damage [52,53]. The complement system therefore 
provides another avenue for exploration into inhibiting exacerbation of chronic 
inflammation, and research into this area is promising for future potential therapies, 
as detailed further in the review by Hammand et al [54]. In addition to complement, a 
recent study of neurogenic inflammation mediator- substance P is also an important 
peptide neurotransmitter to note in TBI, and is further detailed in a review by Vink et 
al. [55].
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It has been established in rodent models of TBI that monocytes and other 
inflammatory cells such as neutrophils enter the brain via the bloodstream [56-58], 
however the literature is currently lacking in definitive confirmation of this process in 
human TBI patients. The recent discovery of microscopic ‘tunnels’ from both mouse 
and human skull bone marrow to the dura and meninges however illuminated 
additional avenues through which these inflammatory cells may invade the brain 
[59]. 
The level of blood brain barrier (BBB) dysfunction and the role it plays in regulating 
this infiltration is likely to differ with severity of injury, and as such is difficult to study 
in humans. Csuka et al. demonstrated that BBB dysfunction was independent of key 
cytokine levels, comparing markers of BBB dysfunction and IL-10 levels in TBI 
patient cerebral spinal fluid (CSF) samples [60]. While in rodent models, Semple et 
al. found that deficiency of a chemokine receptor, CXCR2 was able to attenuate 
neutrophil infiltration [61]. Invading inflammatory cells from the peripheral nervous 
system could be vital to recovery post-insult, or to the perpetuation of a chronic 
inflammatory state. Further research into the roles of these cells in injury would be of 
great benefit to our overall und rstanding of the intricate relationship between BBB 
functionality and inflammation in the brain. 
3.1 Cytokines and glia
Cytokines and chemokines comprise a broad range of small cell signalling proteins 
that are autocrine and paracrine regulators of inflammation in the brain. They are 
released from activated, stressed or dying cells in order to promote survival, 
breakdown cellular membranes, recruit other cells and mark them for repair or 
phagocytosis [62]. Although cytokines are often classified as pro- or anti-
inflammatory, many have been found to be involved in opposing roles, depending on 
the context of their environment and timing after injury [63]. 
The levels of numerous cytokines and chemokines found in TBI patients have been 
characterised in the days after injury in microdialysates. These studies have 
highlighted how specific signalling proteins can be associated with aspects of the 
timing and nature of the inflammatory state of the brain [11]. High IL-1β and TNFα 
are typically associated with the first 24 hours post-injury, related to pro-inflammatory 
mechanisms including apoptosis in many disease models [64-66], while high IL-10, 
and later IL-4 can be associated with the latter stages and are known for their roles 
in repair and promoting cell survival [63]. Also of note is IL-6, an signalling molecule 
which appears at high concentrations in the acute phase of injury, acting as a 
biomarker of inflammation [67].
Microglia are the resident inflammatory cells in the brain and are a key source and 
regulator of the cytokine cascade. When activated in vitro, they can be seen to 
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produce profiles of cytokines which are also often classified as pro- or anti-
inflammatory, namely the M1 and M2 phenotypes [68]. While this characterisation 
has been criticised for its simplicity in describing a complex phenomenon [69], and 
proposals have been made for revisions and alterations to the paradigm [70], they 
are nonetheless useful terms when attempting to understand and refer to the ways in 
which activated microglia and their cytokine profile can be associated with 
reparative, or destructive and phagocytic processes.
In a number of pathological conditions, such as neurodegenerative disorders, both 
M1 and M2 type macrophages have been found to coexist and also from other 
unique phenotypes, and it is likely that most cells sit on a spectrum of activation as 
opposed to these extreme polarised states [70,71]. It can also be difficult to 
distinguish infiltrating monocyte derived macrophages from activated microglia in the 
brain. Levels of ‘CD’ antigens such as CD11b and CD45 [72,73] have been used in 
multiple publications to differentiate these cell types in the past two decades, 
however newer stains and labelling systems such as TMEM119, a specific marker 
for microglia [74,75] are proving valuable. The impact of these infiltrating vs resident 
cells and their inherent neuroprotective or pro-inflammatory role are still being 
debated, and again can change dependant on the severity of injury [76-78]. 
Astrocytes have similarly been assigned A1 and A2 designations of activation in 
recent studies, denoting states of activation in these cells [79]. Their activation is 
closely linked to that of microglia; their role in TBI has been found to be important for 
tissue protection in mild TBI, but not severe TBI [80], and more research is required 
to understand their role in this specific disease context. 
Oligodendrocytes also play a key role post-TBI in remyelination and repair of 
damaged axons, however excessive myelination by dysregulated cells may also lead 
to further damage [81,82]. Direct mechanistic links of oligodendrocytes to the 
inflammatory cascade however are not well defined, although some links have been 
made to metabolic dysfunction in the overall Wallerian degeneration of axons.
4. Synergistic inflammation and metabolic response
The relationship between inflammation and metabolism in TBI remains largely 
unexplored but may have substantial implications for treatment, given that 
metabolism plays a significant role in encouraging the reparative mechanisms of the 
brain. 
Macrophages and other myeloid cells, as previously described in their involvement in 
the inflammatory response, have several metabolic characteristics which distinguish 
the M1 and M2 phenotypes in vitro. When these non-CNS macrophages are 
activated into classical M1 or alternative M2 states by LPS and inflammatory 
cytokines, there is a measured change in metabolism [83], including an increased 
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glucose consumption and lactate production [84,85]. Blocking oxidative metabolism 
in these cells also blocks the M2 phenotype, and drives the macrophage into an M1 
state. Similarly, forcing oxidative metabolism in an M1 macrophage potentiates the 
M2 phenotype [83]. 
The hypothesis for how the change in metabolism affects the inflammatory state, is 
via increased TCA cycle intermediates like succinate and malate. These 
intermediates are responsible for regulating HIF1α, which drives the sustained 
production of the pro-inflammatory cytokine IL-1β. Therefore, the change in 
metabolism and build-up of such intermediates caused more ‘pro-inflammatory’ 
cytokine IL-1β, and therefore an M1-like state. 
Levels of oxygen are also theorised to play an important role in HIFα regulation, 
potentially in a similar way by blocking mitochondrial respiration and causing similar 
build-up of intermediates. Therefore hypoxia-like environments, where mitochondrial 
dysfunction occurs as in TBI, may similarly drive a M1 pro-inflammatory phenotype in 
infiltrating macrophages [83]. Microglia, as the resident macrophage cells of the 
brain also respond similarly to such metabolic impairments. The inhibition of 
mitochondrial respiratory chain complex I in microglia by the compound rotenone led 
to production of mitochondrial ROS and TNFα [86,87]. 
The separation of neuronal and glial cultures is important for investigation of 
metabolic and inflammatory pathways, as the interaction between different cell types 
in response to stress is complex. For example, neuronal death caused by addition of 
mitochondrial inhibitors to cell cultures was not observed unless microglia [88], or 
mixed glia [89] were also present in the culture. Gao et al attributed this 
phenomenon to the release of NADPH oxidase-derived superoxide from activated 
microglia [89], while Mount et al found that antibodies neutralizing the cytokine IFN- 
(produced by the microglia) improved neuronal survival of this mitochondrial stress 
[88]. Phagocytic activity of microglia was also found to be increased by mitochondrial 
inhibitors causing further neuronal loss in mixed neuronal/glial cultures [90]. 
Astrocytes also have different roles and associated response to stress and cytokines 
[91] and may also warrant individual investigation. Mixed cell cultures of neurons and 
glia are therefore necessary in order to gain a ‘whole brain’ perspective, while 
individual cell types in culture can elucidate cell-specific mechanisms.
Further evidence detailing the relationship between inflammation and metabolism is 
found in several disease models. Succinate produced by macrophages in an arthritis 
cell culture model exacerbated the inflammatory response, resulting in increased 
inflammatory cytokine IL-1β [92]. In atherosclerosis mouse models, pre-treatment of 
macrophages with mitochondrial inhibitors abolished the anti-inflammatory effects of 
cytokine IL-4. This indicates that anti-inflammatory mechanisms may be modulated 
by metabolism. However, inhibition of mitochondrial respiration had no effect on 
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inflammatory activation of macrophages by proinflammatory cytokine IFN-γ and 
bacterial inflammatory response generator LPS [85].
More recently, in a Parkinson’s disease model, transmembrane protein 173 or 
‘stimulator of interferon genes’ (STING) was identified as the key signalling molecule 
activated during mitochondrial stress [17]. It also indicated the importance of proteins 
PINK1 and parkin, which aid in removing damaged mitochondria, in order to prevent 
this STING activation.
The relationship between inflammation and metabolism therefore has a strong 
evidence base and holds great potential for manipulation to improve injury and 
disease states.
5. Therapeutic avenues for TBI 
5.1 Standard treatment and monitoring
Despite the progress in research in TBI, there is still no standard effective drug 
treatment for TBI which addresses metabolic dysfunction or the inflammatory 
cascade. Patients receive varying levels of other treatments and medication in 
accordance with their condition, for example antibiotics for pneumonia or infections, 
which may also impact on both their central and peripheral inflammatory state.
Multi-modality monitoring of patients enables real-time observation and intervention 
of disturbances in brain qualities such as pressure and oxygenation, managed both 
medically and surgically. Cerebral microdialysis also allows monitoring of brain 
glucose levels which can be controlled, as well as lactate and pyruvate as detailed 
further in Section 5.3, for indication of metabolic dysfunction. Monitoring of a number 
of biochemical compounds including cytokines have been investigated as potential 
biomarkers for brain injury and have been sparsely incorporated into clinical practice 
[11,93,94]. Ongoing biomarker analysis can assist in detection of secondary harmful 
events, however is not currently used for targeting therapeutics.
The majority of past TBI clinical drug studies focused on more multifunctional global 
brain approaches to influences hormones and steroids, including corticosteroids [95], 
progesterone [96,97], citicoline [98], magnesium sulphate [99], and statins [100] with 
limited success. This may not be due solely to poor efficacy of the therapies, as with 
the anti-inflammatory therapies mentioned below in in 5.2, but instead could be 
related to multiple factors such as issues with animal model to human translation, 
lack of trial optimisation in humans, the heterogeneous nature of TBIs, and difficulty 
in assessing minor improvements in patient outcome. Some illustrative studies of 
previous anti-inflammatory and metabolic therapeutics for TBI are summarised in 
Supplementary Table 1. 
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5.2 Anti-inflammatory therapies
Anti-inflammatory therapies have been extensively studied in TBI, however have yet 
to demonstrate definitive clinical benefit. Wide ranging anti-inflammatory agents have 
been repurposed for studies in TBI, with many of the aforementioned multifunctional 
therapies in 5.1 and Supplementary Table 1, also having a potential anti-
inflammatory effect. The broad immunosuppressant minocycline has been tested 
with limited success in rodent models [101], phase II human trials of spinal cord 
injury [102], and recently in TBI patients [103]. In Scott et al. 2018, minocycline 
treatment managed to reduce markers indicative of microglial activation, however 
also increased markers of neurodegeneration in TBI patients. Common anti-
inflammatory therapeutic ibuprofen caused no significant effects in clinical studies 
[104] and deteriorated cognitive outcomes in rodent models of TBI [105]. 
Targeted anti-inflammatory therapies are also being explored in TBI. These inhibit 
the action of specific cytokines using antibodies and synthetic receptor antagonists. 
Tumour necrosis factor (TNF), inhibition has shown improvements across multiple 
clinical domains following treatment of both stroke and TBI patients in a large cohort 
study [106]. This study, however, had several limitations and a small TBI cohort, and 
hence a randomized, placebo-controlled trial is necessary to further characterise this 
outcome. The inhibition of cytokines IL-1α and IL-1ß have similarly been explored, 
due to their significant ‘pro-inflammatory’ effects with success in pre-clinical rodent 
models of TBI [107,108]. IL-1ra, the naturally occurring inhibitor of IL-1α and IL-1ß, 
when given subcutaneously also reduced markers of peripheral inflammation in 
subarachnoid haemorrhage patients [109]. Evidence of IL-1ra relationship with TBI 
patient outcome was established in a small study of 15 patients by Hutchinson et al. 
2007, in which higher endogenous IL-1ra levels correlated to favourable outcomes 
[110]. Supplementing IL-1ra levels in the brain with Anakinra (recombinant IL-1ra) 
has also proven to be safe in TBI patients, however, initial findings suggest that it 
produces an increased ‘pro-inflammatory’ or ‘M1’ cytokine profile compared to 
untreated patients [50,111]. These effects will be further explored in a dose 
optimisation study of recombinant IL-1ra in a placebo controlled randomised trial by 
Helmy et al. (estimated completion 2023). The extent of the numerous novel pre-
clinical anti-inflammatory studies are beyond the scope of this review, however is 
well detailed in other publications [112-114].
Nonspecific anti-inflammatories may be able to reduce the negative effects of an 
overwhelming cytotoxic cascade, however, they may also dampen repair and cell 
survival mechanisms. Equally, it can be difficult to produce a measurable effect in 
humans when targeting only a single cytokine or chemokine, as they act 
synergistically, and it can be difficult to tease out specific cytokine functions within a 
complex system [115]. Antibodies or increase of specific cytokines could also 
potentially trigger the opposite effect to that intended, depending on dose, timing, 
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disease context and environmental factors. For example, cells may have their own 
feedback loop for limiting further transcription and production of cytokines [116,117], 
which anti-inflammatory therapies may interrupt. 
Despite their targeting limitations, monitoring the effect that any potential TBI 
treatments may have on these signalling proteins is an important feature to 
investigate. As this review details, one potential avenue for anti-inflammatory action 
is through specific metabolic targeting as a dual action therapy.
5.3 Metabolic Supplementation 
The brain’s metabolic status post-TBI has been studied in great detail with spectral 
analysis techniques used noninvasively and also in the analysis of patient samples 
such as serum, CSF and microdialysis fluid. These techniques include; magnetic 
resonance spectroscopy (MRS) [118], mass spectrometry [119,120], and nuclear 
magnetic resonance (NMR) with both unlabelled [121] and 13C labelled substrates 
[34,122]. The results of these studies highlight potential metabolic pathways which 
could be targeted by supplementation to improve brain energy status.
There is promising evidence currently emerging for metabolic supplementation, and 
its reinforcement of the ‘normal’ (non-trauma) homeostasis of the brain [123]. The 
impact of these substances on the inflammatory cascade, however, is yet to be 
demonstrated in most cases. Studies need to further investigate whether these 
agents will aid an overactive immune system perturbing the brain or encourage a 
more reparative environment. 
5.3.1 Glucose
Brain glucose is of significant importance post-TBI, with patients often presenting 
with cerebral extracellular glucose levels outside the normal range, correlating with 
worse outcomes. High glucose levels identified in patient serum were associated 
poorer outcomes in patients [124] as were persistent low extracellular glucose levels 
in brain microdialysates [125]. Brain glucose is directly influenced by blood glucose 
levels and glutamate pathogenicity increases when blood glucose levels are low 
[126]. It is important to note, that glucose is of utmost importance for overall brain 
metabolism, and although additional substrates we are suggesting for 
supplementation may assist in brain metabolism in the acute phase post-TBI, 
glucose levels must first be corrected if at abnormal levels. The addition of glucose 
as metabolic rescue agent is therefore a critical factor in patient outcome, and many 
centres use glucose control in their standard TBI protocols, aiming for blood glucose 
levels of 4-7 mM [127]. However, controlling glucose levels too tightly in patients has 
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also been found to have no benefits in terms of decreased mortality [128] and 
increased incidences of metabolic crisis [129,130].
5.3.2 SuccinateSuccinate is another energetic molecule which has been explored 
as a therapeutic supplement in TBI. It acts at complex II of the Electron Transport 
Chain (ETC), in the mitochondria, located downstream potential sites of damage 
such as at complex I as previously described in 2.2. Succinate is converted into 
fumarate by the enzyme succinate dehydrogenase, as an integral part of the TCA 
cycle. Succinate, the anion of succinic acid, has multiple biological roles as a 
metabolic intermediate; as part of the production of ATP and as a signalling molecule 
of the cellular metabolic state [131]. 
It has been shown that succinate supplementation improves TBI brain chemistry, in a 
mixed glial model, indicated by biomarkers and reduced the LPR after exposure to 
stress by rotenone [132], highlighting its potential for use in TBI treatment. There is 
evidence to suggest, however, that succinate can have negative effects in hypoxic 
conditions, where it can build up in tissue, leading to the production of excessive 
reactive oxygen species (ROS) when oxygen is returned [131,133]. These studies 
however often used artificial dimethyl or diethyl succinate which is more cell 
permeable and may have further implications beyond that of natural metabolic 
utilisation, unlike the disodium salt. Ischemia reperfusion-induced injuries are also 
less common in TBI patients with modern neurocritical care that includes adequately 
managed brain oxygen supply as was the case in patients in a clinical study of 
succinate [123], and as such this succinate build up would be unlikely to occur. 
Areas to be carefully considered during implementation of succinate as a therapeutic 
supplement therefore include ensuring adequate tissue oxygenation and reviewing 
the implications of using artificial features in such as methyl- and ethyl- groups on 
such molecules. Preliminary studies of disodium succinate use in TBI patients have 
provided a promising outlook for its use in delivery via microdialysis catheter, 
demonstrating effectiveness in lowering of the LPR [123] and improving the 
NADH/NAD+ redox state of the brain [134]. In a patient with MELAS (mitochondrial 
myopathy, encephalopathy, lactic acidosis and stroke-like episodes), oral succinate 
therapy (6 g/day, for more than 30 months) was associated with freedom from the 
stroke-like episodes and convulsions that had afflicted this patient prior to succinate 
therapy [135]. 
Succinate’s effect on inflammation, however, requires further investigation as in mice 
and in vitro experiments succinate enhanced pro-inflammatory IL-1β production 
[131]. Succinate oxidation and subsequent ROS generation has also been linked to 
‘pro-inflammatory’ macrophage activation [136]. However, in a recent paper using 
neural stem cells, when succinate was released from mononuclear phagocytes, it 
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initiated a chain of signalling resulting in anti-inflammatory effects [137], again 
highlighting the importance of context when assessing such complex systems.
5.3.3 Lactate
Mounting evidence indicates that lactate may be an efficient energy substrate for 
neurons and contribute to maintaining synaptic transmission, particularly during 
periods of intense activity [138] via the ANLS as previously described in 2.1. Its use 
as a supplement in TBI has been explored in both animal [139] and human models 
[27], although warrants additional clinical study in this context. The mechanism of 
lactate as a signalling molecule has also been explored with several different 
functionalities identified in depolarisation, currents and action potential activity [140]. 
Recent studies have also highlighted additional roles relevant to TBI, finding that L-
lactate supplementation of cell culture model medium increased mRNA expression 
of genes regulating synaptic plasticity and neuroprotection [141].
High concentrations of lactate as a therapeutic agent would likely be tolerated well 
by human cells, as although non-wounded tissue in humans and rodents contain 
lactate at concentrations of 0.5–2 mM, wound levels can be at 5–15 mM or higher 
[142]. Lactate infusion studies in healthy patients which elevated blood plasma levels 
to 4 mM have also been conducted and shown a potential preference for lactate over 
glucose for brain cell metabolism [143].
Lactate’s role in wound healing is one of particular interest to TBI- important in the 
regulation of VEGF and stimulating collagen deposition for formation of blood 
vessels and healing in cell culture models [142]. It was found that high lactate levels 
when accompanied by normoxic conditions, stimulated optimal blood vessel 
formation [142]. In subarachnoid haemorrhage (SAH), where blood vessel healing is 
critical, a microdialysis study in patients showed a pattern of elevated brain lactate 
and cerebral hyperglycolysis was associated with good recovery [144], while 
cerebral hypoxic lactate was associated with an increased mortality.
In early studies, Pellerin and Magistretti attributed brain lactate levels largely to 
astrocyte activity as blood-borne lactate does not easily cross the BBB and was 
therefore not a likely source in ‘healthy’ brain [24]. However, in brain perturbations 
such as TBI and SAH, periods of endogenous lactate import have been found to 
occur, which may help support injured brain [34,121,144]. 
In TBI, lactate infusions have been studied, not specifically for metabolic 
enhancement, but as an alternative for lowering intercranial pressure [145]. 
Metabolic inferences however have been made as patients who are initially more 
metabolically ‘stressed’ (i.e. an elevated LPR), had higher brain glucose 
concentrations after receiving hypertonic lactate infusion, than patients with lower 
Page 14 of 39
URL: https://mc.manuscriptcentral.com/ern   Email: IERN-peerreview@journals.tandf.co.uk





























































For Peer Review Only
15
initial LPR [146]. This decreased glucose consumption indicates a preferential use of 
lactate in these elevated LPR cases, which could be beneficial for assisting energy 
production in more perturbed brains. The high lactate concentrations may also have 
a self-regulating effect, driving less lactate production by cells overall. This 
hyperosmolar nature of the infusion however could also be playing a key role in 
creating a more favourable environment for the brain and also reducing stress on 
brain cells [147]. Therefore, additional studies on non-hypertonic lactate would assist 
in better describing its individual role in these cases. This addition of lactate to the 
system would artificially increase the L/P ratio - a measure typically associated with 
worse outcome, and other biomarker measures would also have to be used for such 
studies. 
5.3.4 Acetate
Acetate is another simple metabolite that is transported across the cellular 
membrane to be used in the TCA cycle and in the production of phospholipids. It is 
estimated that circulating acetate levels may contribute up to 10%–15% of the basal 
energy demands of astrocytes [148]. This increased acetate processing (also 
upregulated in tumour growth [149]) may be important for meeting the bioenergetic 
demands in TBI. In addition to acetate’s role as an energy substrate, it is noted to 
increase during stress, hypoxia exposure, and glucose deprivation. It has also been 
linked to HIF-2 signalling- required for lipid synthesis, proliferation, migration, and 
invasion in cancer cells in vitro [150]. 
Dichloroacetate (DCA) has been used to inhibit pyruvate dehydrogenase kinase. 
This decreases the conversion of pyruvate to lactate, promoting aerobic glycolysis in 
treatment of inherited mitochondrial disorders, pulmonary hypertension and solid 
tumours [151,152]. Several studies have been done on DCA and similar acetate-
derived molecules to reduce lactate production in vitro [153,154], which may be 
applicable to TBI. Glyceryltriacetate (GTA), another form of bioavailable acetate, has 
similarly been used in rodent models of TBI, where it improved motor performance 
and increased ATP levels [155].
One difficulty with acetate supplementation in humans, however, is side effects such 
as alkalosis. Plasma acetate concentration in humans varies from 0.05 to 0.25 mM 
under resting conditions (and up to 1 mM after alcohol consumption), while the 
acetate concentration in mouse and rat plasma ranges from 0.20 to 0.30 mM, and as 
such rodents may tolerate supplementation better in pre-clinical studies [156]. 
Sodium acetate infusion in healthy human subjects at up to 2 mM in plasma 
produced a significant rise in plasma pyruvate, lactate, and α-hydroxybutyrate 
concentrations, indicating metabolic use, however this occurred along with 
temporary alkalosis [157]. High concentration daily infusions of DCA in humans was 
also associated with peripheral neuropathy [158,159]. 
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Investigating the role of acetate in the metabolic and inflammatory response to TBI 
models could highlight another pathway in which we could attempt to regulate these 
processes, however its use as a supplement is currently limited in terms of 
concentration due to side-effects (see above).
5.3.5 Other metabolic supplementation pathways for consideration
Pyruvate is another candidate that has been clearly identified as a potential 
supplement for increasing metabolic substrate availability, which would effectively 
impact LPR. Pyruvate would also bypass the glycolysis step and potential diversion 
to lactate that can occur with glucose, however pyruvate may need to be given in a 
semi-altered form (e.g. ethyl pyruvate [160]) as pyruvate in solution can self-react, 
forming dimers (e.g. parapyruvate) that could inhibit the TCA cycle [161]. Ethyl 
pyruvate has been tested in pre-clinical rodent models of TBI, and has been found to 
improve cognitive function [162] and decrease neuronal loss [163], while sodium 
pyruvate can also decrease neuronal loss and attenuate metabolic dysfunction 
[164,165]. HMGB1, an inflammatory protein which further increases release of 
cytokines, was also found to be reduced by ethyl pyruvate in a study of TBI in rats 
[166]. Human cell culture studies have also identified pyruvate as a possible 
therapeutic scavenger for free radicals created during NOS activity [167].
Ascorbic acid is another molecule warranting further investigation as a metabolic 
supplement, due to its potential role as a ‘switch’ in metabolic molecule uptake in 
neurons from glucose to lactate and ability to scavenge ROS [168,169].
The brain-gut axis is another pathway that is increasingly represented in the 
literature and may also need to be taken into consideration due its effects on 
inflammation and neurodegenerative disease [170]. Supplementing microbiota could 
have indirect effects on inflammation and metabolism. The brain-gut axis is outside 
the scope of this review, however is recognised in multiple sclerosis [171], and some 
preliminary studies in TBI [172,173]. 
5.4 Metabolic attenuation 
As well as metabolic supplementation, metabolic attenuation could also have 
potential to have therapeutic effects on the post-TBI brain by regulating excessive 
and potentially harmful cell processes.
5.4.1 Glutamate 
Glutamate is the most common neurotransmitter released by neurons for cell 
signalling and is linked to multiple cell processes. The astrocyte-neuron lactate 
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shuttle hypothesis links increased glutamate to stimulation of astrocyte metabolic 
pathways [24,138, 174], as previously described in Figure 2. In this hypothesis, 
astrocytes take up glutamate for processing, which also increases astrocytic glucose 
uptake.
In patients with TBI, increased glucose metabolism and LPR is associated with 
poorer outcomes, and increased glutamate may be contributing to this metabolic 
dysfunction via the ANLS pathway. Glutamate levels have been shown to rise in 
severe TBI cases, correlating with poorer outcomes [15]. Glutamate transporters 
have also been found to be decreased in astrocytes following TBI [175]. Acute 
glutamate release is also associated with post-traumatic epilepsy and subsequent 
neuronal cell death, established in both rodent models [176,177], and in 
approximately 20% of human closed head injury patients [178]. In TBI patients, these 
epilepsy-associated electrophysiological disturbances are also associated with 
metabolic disturbances in terms of increased LPR [179]. This increase in 
extracellular glutamate increases excitotoxicity [180] and further contributes to the 
brains pathological state.
In addition to metabolism, pathological glutamate release is also linked to 
inflammatory pathways, as the local levels of this molecule have been associated 
with pro- or anti-inflammatory activation of cultured microglial cells [181]. This is 
hypothesised to act through glutamate’s effect on the production of free radicals from 
nitric oxide synthase (NOS) activity [182]. 
Attenuating glutamate release to inhibit post-TBI damage and epilepsy is currently in 
early stages of investigation. Overexpression of the glutamate transporter, GLT-1, in 
mouse models significantly reduces ischemia-induced glutamate overflow, resulting 
in decreased cell death and improved recovery [183]. The impact of such 
experiments attenuating glutamate on the brain’s metabolic status and potential 
inflammatory implications would also be of great interest. Similarly, the effect of any 
other supplementation on glutamate levels would be important to consider in clinical 
studies.  
5.4.2 Cyclosporine
Cyclosporine is used in patients receiving transplants due to its immunosuppressive 
properties, however has since been explored further for drug repurposing. It was 
discovered to have additional metabolic functions, inhibiting mitochondrial membrane 
permeability and excessive ROS production. Cyclosporine was recently shown to 
exhibit these metabolic effects in pre-clinical rat [184] and porcine [185] models of 
TBI, reducing injury lesion volume and improving mitochondrial function. Previous 
studies in TBI patients have also found cyclosporine to decrease LPR [186]. 
Cyclosporine’s safety for use in TBI patients have been shown in phase II clinical 
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data [187,188] with no significant difference in adverse effects compared to controls 
[189]. However, improved neuroprotection or cognitive outcome in humans is yet to 
be confirmed. This effect may be largely due to cyclosporine treatment 
corresponding to an increase in glucose levels detected in the microdialysates [162]. 
The combination of metabolic and anti-inflammatory actions marks cyclosporine a 
very noteworthy dual-acting therapy for future studies.
6. Conclusion and future potential: metabolic modulation as a dual-action anti-
inflammatory therapy 
There is a clearly emerging field of work highlighting the relationship between 
metabolism and inflammation with implications for many disease states. The 
diverging evidence for use of metabolic intermediates such as glucose and succinate 
as supplements highlights the importance of the disease context and brain 
environment in their application, and also their significant impact on brain 
homeostasis and patient outcome. Further studies of new metabolic intermediates 
supplements, or new drugs for attenuation of adverse metabolic tendencies, and 
how these candidates may alter inflammatory signalling are needed. This emerging 
field is of particular interest for their use in acute injury and recovery, as there is still 
no effective neuroprotective drug treatment for TBI. Investigation into these links and 
pathways are still in their early stages, however have great potential for new 
treatment avenues for further focus in neurological injury and disease.
7. Expert commentary
Understanding the nature of the abnormal cerebral metabolism following TBI, and its 
relationship with brain inflammation, will provide essential information for designing 
therapies. The results would have implications not only for neurocritical care but also 
for the long-term disability and accelerated onset of neurodegenerative diseases 
(e.g. dementia and Parkinson’s) in post-TBI patients. Studies suggest that after the 
initial few days post-TBI there may still be an on-going and persistent inflammatory 
process. TBI patients show varying degrees of disability months or even years post-
injury, and chronic low-grade brain inflammation may conceivably play a role. 
Mitochondrial function is known to play a key role in in vitro repolarization of such M1 
cells to an M2 phenotype. Research in inflammation in TBI animal models has 
received considerable success and attention yet there is lack of evidence for benefit 
in human TBI patients. In general, TBI research suffers from a “failure to translate” 
whereby drugs that looked promising in animals have failed in clinical trials. Modern 
clinical technologies such as microdialysis and advanced scanning, in combination 
with laboratory-based instrumentation e.g. multiplex immuno-analysers for cytokine 
profiling and metabolic flux analysers for real-time measurements on cells, provide 
us with the means to further study TBI in patients, and should in turn inform design of 
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appropriate therapies. In particular, the possibility of improving mitochondrial 
function, promoting efficient oxidative metabolism, which in turn ameliorates brain 
inflammation, is an considerable therapeutic goal.
8. Five year view
The prospect of using metabolic supplementation to ameliorate secondary injury 
including inflammation after TBI merits further exploration in model systems, and in 
carefully controlled clinical studies in TBI and non-TBI individuals. Phase III studies 
of clinical outcomes are costly, and demand time, resources and large numbers of 
patients. It is therefore important that adequate Phase I and Phase II clinical studies 
are performed employing appropriate measurements and biomarkers. These include 
multiplex immunoassays, metabolic monitoring techniques such as microdialysis and 
ex-vivo analysis e.g. ISCUSflex (a bedside clinical microdialysis analyser that 
performs enzymatic colorimetric assays for glucose, lactate, pyruvate, glutamate and 
glycerol), NMR, mass spectrometry, and in-vivo scanning (e.g. MRI and MRS).  
Metabolic therapy for TBI patients is an exciting prospect for neurocritical care and 
for alleviating long-term disability and neurodegeneration in post-TBI patients. 
Moreover, metabolic therapy may also have potential for treating other conditions 
where evidence suggests that mitochondrial function is disrupted, including “ageing-
related” diseases such as dementia and Parkinson’s, which often occur at an earlier 
age in brain injury survivors compared to those without any previous brain injury.
Key Issues
 Traumatic Brain Injury patients have no standard therapies to address the 
metabolic or inflammatory effects of their disease in the short or long term.
 Metabolic dysfunction- identified by a high lactate/pyruvate ratio despite 
adequate brain glucose and oxygenation, has been characterised as 
occurring in a subset of patients.
 Inflammatory system activation can continue for months or years post-TBI, 
needing both acute and long-term pharmacological interventions. 
Inflammation immediately post-TBI is difficult to manage due to complex 
pleotropic nature of the signalling molecules, cytokines and chemokines.
 Links between inflammatory cell actions and their metabolism have been 
found in cell culture models of neuronal and non-neuronal cells. The further 
study of these links in both single cell and ‘whole brain’ is needed to tease out 
the specific metabolism/inflammation pathways and links. 
 Metabolic supplementation is a potential to impact on inflammation and solve 
the energy crisis in the brain. Glucose control is important for clinical outcome, 
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although strict control of such levels increase metabolic crisis. Succinate has 
potential to ameliorate metabolic stress, however, only in adequately 
oxygenated environments. Other supplementation candidates are also 
emerging, yet further research is needed.
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Figure Legends
Figure 1. Schematic of glucose energetic metabolism pathways in the cell. 
Glycolysis, which produces two molecules of ATP per molecule of glucose, is 
followed by oxidative phosphorylation of pyruvate (in the mitochondrion, through the 
tricarboxylic acid (TCA) cycle and electron transport chain (ETC), which produces 34 
molecules of ATP, or LDH processing of pyruvate to lactate, which produces no 
molecules of ATP. Diagram copyright © 2018 Monica J. Killen, reproduced here with 
her permission. 
Figure 2. The astrocyte-neuron lactate shuttle (ANLS). Glucose is delivered via the 
brain vasculature and can be taken up by both neurons and astrocytes for 
processing. Both cell types are able to process this glucose to pyruvate, which can 
then be delivered for subsequent ATP generation in the mitochondria. Astrocytes, 
however, can also supplement neuronal energy production by converting pyruvate to 
lactate and transporting it to the neurons via monocarboxylate transporters (MCT). 
Neurons then process the lactate back to pyruvate for mitochondrial processing. This 
process is also linked to the recycling of synaptic glutamate and sodium uptake in 
astrocytes, which in turn stimulates the need for increased glucose import. 
Reproduced from [14]: Magistretti, P.J. and Allaman I., A Cellular Perspective on 
Brain Energy Metabolism and Functional Imaging. Neuron, 2015. 86(4): p. 883-901. 
Copyright © 2015 Elsevier, reproduced with permission from Elsevier.
Figure 3. The phased cell-mediated response to acute brain injury. A complex 
inflammatory cascade develops through interaction between several physiological 
compartments [cerebrospinal fluid (CSF), brain parenchyma, and vascular]. The 
initial response is first triggered by signalling molecules known as danger-associated 
molecular patterns (DAMPs) which are released into the extracellular environment 
post-injury. This stimulates resident microglia and astrocytes to produce cytokines, 
chemokines, and other potent chemotactic substances which promote the 
recruitment of peripheral nervous system cells. Monocytes and neutrophils enter the 
brain parenchyma through the permeable blood–brain barrier (BBB), and can further 
intensify the cytotoxic environment with their own secretion of signalling proteins. An 
ongoing cytokine release initiates a long-term inflammatory process, where typically 
we see an increase in M2 ‘reparative’ cell phenotype, as opposed to the initial pro-
inflammatory M1 activated cells. However, chronic inflammation and overactivation 
of this system can lead to injurious outcomes, such as epilepsy, depression, and 
auto-immunization toward brain-enriched antigens. Reproduced from [33]: Thelin, 
E.P., et al., Monitoring the Neuroinflammatory Response Following Acute Brain 
Injury. Frontiers in Neurology, 2017. 8: p. 351. Copyright © 2017  Thelin, Tajsic, 
Zeiler, Menon, Hutchinson, Carpenter, Morganti-Kossmann and Helmy, published 
open-access under a Creative Commons Attribution License (CC-BY).
Page 21 of 39
URL: https://mc.manuscriptcentral.com/ern   Email: IERN-peerreview@journals.tandf.co.uk





























































For Peer Review Only
22
Supplementary Table 1. Inflammatory and Metabolic Neurotherapeutics in TBI
Treatment Effect Author Journal Type Cohort/Model Outcome
Perispinal 
Etanercept (PSE)
TNF inhibition Tobinick 
et al. 
2012[106]
CNS Drugs, 26(12): 
p. 1051-1070.
Clinical 617 stroke, 12 TBI 
patients. 
In the TBI cohort, motor impairment and 
spasticity were statistically significantly 
reduced. in the stroke group, improvements 
in motor impairment, spasticity, sensory 
impairment, cognition, psychological/ 




Brain, 141(2): p. 459-
471.
Clinical 15 patients >6 
months post-TBI
Reduces chronic microglial activation after 





Brain, 135(4): p. 
1224-1236.
Clinical Spinal cord Injury. 
27 minocycline, 
25 placebo control
Greater motor recovery in cervical but not 
thoracic injury.
Minocycline Reduced inflammation and 
mitochondrial stabilisation. 
Inhibition of microglial activation 
and proliferation, reduced 
excitotoxicity, reduced neuronal 
and glial apoptosis, 
neutralization of oxygen 
radicals, nitric oxide synthase 
inhibition, metalloproteinase 
inhibition. 















Journal of Cerebral 
Blood Flow & 
Metabolism, 34(5): p. 
845-851.




Safety in patients, penetration of brain from 
initial subcutaneous injection. Difference in 















Antibodies to IL-1ß 
and IL-1α
Decreased IL-1ß and IL-1α 
function 















Journal of Surgery, 
209(6): p. 921-926.
Clinical 65 Ibuprofen, 130 
control















Worsened cognitive outcome, no effect on 
hippocampal and cortical tissue loss.
Cyclosporine Preserve mitochondrial 








Clinical 50 severe TBI 
patients
Improved brain chemistry (lower LPR)
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British Journal of 
Anaesthesia, 93(6): 
p. 761-767.
Clinical 391 head injured 
patients before, 
452 patients after 
protocol 
implemented
Relative risk reduction in intensive care 
mortality with introduction of tight glycaemic 




Journal of Cerebral 
Blood Flow & 
Metabolism, 37(7): p. 
2626-2638.






Clinical 8 TBI patients Improved brain chemistry (lower LPR, 







Clinical MELAS patient 
case study
Complete control of convulsions.
Succinate Supplement mitochondrial 
Complex II activity
Giorgi-







Rat cell culture Improved metabolic performance (lower 
LPR, improved mitochondrial respiration)






Clinical 9 severe TBI 
patients, 5 control
Lactate metabolised to pyruvate, before 
entering the TCA cycle, no difference 








Clinical 24 severe TBI 
patients







Medicine, 35(3): p. 
471-479.
Clinical 34 severe TBI 
patients
More effective reduction of ICP and better 















increased the levels of both NAA and ATP 
and improved motor performance.
Sodium Pyruvate 













SP attenuates cerebral metabolic 
depression and both SP and EP decrease 
neuronal loss.
Ethyl Pyruvate Neuroprotection via MMP-9 
suppression and altered anti-
inflammatory effects.










Improved sensorimotor and cognitive 
functions, ameliorated brain tissue damage, 
attenuated BBB breach and brain edema.
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Figure 1. Schematic of glucose energetic metabolism pathways in the cell. Glycolysis, which produces two 
molecules of ATP per molecule of glucose, is followed by oxidative phosphorylation of pyruvate (in the 
mitochondrion, through the tricarboxylic acid (TCA) cycle and electron transport chain (ETC), which 
produces 34 molecules of ATP, or LDH processing of pyruvate to lactate, which produces no molecules of 
ATP. Diagram copyright © 2018 Monica Killen, reproduced here with her permission. 
301x280mm (150 x 150 DPI) 
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Figure 2. The astrocyte-neuron lactate shuttle (ANLS). Glucose is delivered via the brain vasculature and can 
be taken up by both neurons and astrocytes for processing. Both cell types are able to process this glucose 
to pyruvate, which can then be delivered for subsequent ATP generation in the mitochondria. Astrocytes, 
however, can also supplement neuronal energy production by converting pyruvate to lactate and 
transporting it to the neurons via monocarboxylate transporters (MCT). Neurons then process the lactate 
back to pyruvate for mitochondrial processing. This process is also linked to the recycling of synaptic 
glutamate and sodium uptake in astrocytes, which in turn stimulates the need for increased glucose import. 
Reproduced from [14]: Magistretti, P.J. and Allaman I., A Cellular Perspective on Brain Energy Metabolism 
and Functional Imaging. Neuron, 2015. 86(4): p. 883-901. DOI 10.1016/j.neuron.2015.03.035, Copyright 
© 2015 Elsevier, reproduced with permission from Elsevier (CC-BY-NC-ND). 
172x103mm (300 x 300 DPI) 
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Figure 3. The phased cell-mediated response to acute brain injury. A complex inflammatory cascade 
develops through interaction between several physiological compartments [cerebrospinal fluid (CSF), brain 
parenchyma, and vascular]. The initial response is first triggered by signalling molecules known as danger-
associated molecular patterns (DAMPs) which are released into the extracellular environment post-injury. 
This stimulates resident microglia and astrocytes to produce cytokines, chemokines, and other potent 
chemotactic substances which promote the recruitment of peripheral nervous system cells. Monocytes and 
neutrophils enter the brain parenchyma through the permeable blood–brain barrier (BBB), and can further 
intensify the cytotoxic environment with their own secretion of signalling proteins. An ongoing cytokine 
release initiates a long-term inflammatory process, where typically we see an increase in M2 ‘reparative’ cell 
phenotype, as opposed to the initial pro-inflammatory M1 activated cells. However, chronic inflammation 
and overactivation of this system can lead to injurious outcomes, such as epilepsy, depression, and auto-
immunization toward brain-enriched antigens. Reproduced from [33]: Thelin, E.P., et al., Monitoring the 
Neuroinflammatory Response Following Acute Brain Injury. Frontiers in Neurology, 2017. 8: p. 351. 
Copyright © 2017  Thelin, Tajsic, Zeiler, Menon, Hutchinson, Carpenter, Morganti-Kossmann and Helmy, 
published open-access under a Creative Commons Attribution License (CC-BY). 
358x234mm (144 x 144 DPI) 
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Supplementary Table 1. Inflammatory and Metabolic Neurotherapeutics in TBI
Treatment Effect Author Journal Type Cohort/Model Outcome
Perispinal 
Etanercept (PSE)
TNF inhibition Tobinick et 
al. 2012 
[106]
CNS Drugs, 26(12): 
p. 1051-1070.
Clinical 617 stroke, 12 TBI 
patients. 
In the TBI cohort, motor impairment and 
spasticity were statistically significantly 
reduced. in the stroke group, improvements 
in motor impairment, spasticity, sensory 
impairment, cognition, psychological/ 
behavioural function, aphasia and pain.
Scott et al. 
2018 [103]
Brain, 141(2): p. 
459-471.
Clinical 15 patients >6 
months post-TBI
Reduces chronic microglial activation after 





Brain, 135(4): p. 
1224-1236.
Clinical Spinal cord Injury. 
27 minocycline, 
25 placebo control
Greater motor recovery in cervical but not 
thoracic injury.
Minocycline Reduced inflammation and 
mitochondrial stabilisation. 
Inhibition of microglial activation 
and proliferation, reduced 
excitotoxicity, reduced neuronal 
and glial apoptosis, 
neutralization of oxygen 
radicals, nitric oxide synthase 
inhibition, metalloproteinase 
inhibition. 














Journal of Cerebral 
Blood Flow & 
Metabolism, 34(5): 
p. 845-851.




Safety in patients, penetration of brain from 
initial subcutaneous injection. Difference in 















Antibodies to IL-1ß 
and IL-1α
Decreased IL-1ß and IL-1α 
function 













Journal of Surgery, 
209(6): p. 921-926.
Clinical 65 Ibuprofen, 130 
control















Worsened cognitive outcome, no effect on 
hippocampal and cortical tissue loss.
Cyclosporine Preserve mitochondrial 








Clinical 50 severe TBI 
patients
Improved brain chemistry (lower LPR)
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Glucose Glycaemic control Clayton et 
al. 2004 
[127]
British Journal of 
Anaesthesia, 93(6): 
p. 761-767.
Clinical 391 head injured 
patients before, 
452 patients after 
protocol 
implemented
Relative risk reduction in intensive care 
mortality with introduction of tight glycaemic 
control (blood glucose 4-7 mmol litre−1)
Jalloh et al. 
2017 [123]
Journal of Cerebral 
Blood Flow & 
Metabolism, 37(7): 
p. 2626-2638.






Clinical 8 TBI patients Improved brain chemistry (lower LPR, 







Clinical MELAS patient 
case study
Complete control of convulsions.
Succinate Supplement mitochondrial 
Complex II activity
Giorgi-Coll 






Rat cell culture Improved metabolic performance (lower 
LPR, improved mitochondrial respiration)






Clinical 9 severe TBI 
patients, 5 control
Lactate metabolised to pyruvate, before 
entering the TCA cycle, no difference 







Clinical 24 severe TBI 
patients
Improvement of brain energetics.Hypertonic Lactate Reduce secondary intracranial 
hypertension, cerebral 
energetics
Ichai et al. 
2009 [145]
Intensive Care 
Medicine, 35(3): p. 
471-479.
Clinical 34 severe TBI 
patients
More effective reduction of ICP and better 





Arun et al. 
2010 [155]







increased the levels of both NAA and ATP 
and improved motor performance.
Sodium Pyruvate 




Moro et al. 
2016 [164]
Brain Research, 





SP attenuates cerebral metabolic 
depression and both SP and EP decrease 
neuronal loss.
Ethyl Pyruvate Neuroprotection via MMP-9 
suppression and altered anti-
inflammatory effects.









Improved sensorimotor and cognitive 
functions, ameliorated brain tissue damage, 
attenuated BBB breach and brain edema.
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